大剂量维生素C联合维生素B1辅助治疗脓毒症休克患者的效果

doi:10.3760/cma.j.issn.1007-1245.2023.08.020

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (8): 1122-1126.DOI: 10.3760/cma.j.issn.1007-1245.2023.08.020

大剂量维生素C联合维生素B1辅助治疗脓毒症休克患者的效果

王玉亮刘建华唐绮云

广州市番禺区何贤纪念医院重症医学科，广州　511400

收稿日期:2022-08-17 出版日期:2023-04-15 发布日期:2023-05-01
通讯作者: 王玉亮，Email：39601503@qq.com
基金资助:
广州市番禺区科技计划项目（2021-Z04-072）

High-dose vitamin C combined with vitamin B1 for patients with septic shock

Wang Yuliang, Liu Jianhua, Tang Qiyun

Department of Critical Care Medicine, Hexian Memorial Hospital of Panyu District, Guangzhou 511400, China

Received:2022-08-17 Online:2023-04-15 Published:2023-05-01
Contact: Wang Yuliang, Email: 39601503@qq.com
Supported by:
Project of Plan of Science and Technology at Panyu District, Guangzhou (2021-Z04-072)

摘要/Abstract

摘要：

目的　探讨大剂量维生素C联合维生素B1辅助治疗脓毒症休克患者的效果。方法　选择2022年1月至8月期间于广州市番禺区何贤纪念医院ICU诊治的90例脓毒症休克患者进行随机对照试验，按照随机数字表法分为对照组（生理盐水）45例，试验组（维生素C+维生素B1）45例。其中对照组男25例，女20例，年龄43～97（74.0±16.64）岁，按照最新的脓毒症和脓毒症休克指南进行液体复苏、抗感染治疗、原发病治疗等；试验组男33例，女12例，年龄35～94（68.0±13.44）岁，在集束化治疗的基础上加予大剂量维生素C及维生素B1。对比两组入住ICU时（T0）及治疗72 h后（T1）的左室射血分数（LVEF）、心排血量（CO）、三尖瓣收缩期位移（TAPSE）等超声结果及T淋巴细胞计数（CD3+、CD4+T、CD8+T）、CD4+/CD8+比例、TNF-α等数据及两组患者ICU住院期间的预后结局。统计学方法采用χ²检验、秩和检验、t检验。结果　试验组T1的TNF-α低于对照组［12.96（10.72，19.6）比17.95（11.015，34.75）］，差异有统计学意义（Z=-1.96，P<0.05）；试验组的CD3+、CD4+、CD8+均高于对照组，差异均有统计学意义（Z=-3.58、-3.15、-3.43，均P<0.05）；对照组T1的CD8+较T0下降（Z=-2.26，P<0.05）。试验组T1的CD3+、CD4+、CD8+高于T0，差异均有统计学意义（Z=-3.77、-3.89、-2.91，均P<0.05）。试验组好转率高于对照组［71.11%（32/45）比51.11%（23/45）］，两组的预后比较，差异有统计学意义（χ²=8.407，P<0.05）。结论　大剂量维生素C联合维生素B1可提升脓毒症休克患者的T淋巴细胞亚群数量，提高患者免疫功能，一定程度上减少TNF-α的产生，改善患者预后。

关键词:

脓毒症休克, 淋巴细胞亚群, 大剂量维生素C, 维生素B1

Abstract:

Objective　To explore the effect of high-dose vitamin C combined with vitamin B1 for patients with septic shock. Methods　Ninety patients with septic shock who were diagnosed and treated in ICU, Hexian Memorial Hospital of Panyu District from January 2022 to August 2022 were selected for the random control trial. They were divided into a control group (normal saline) and an experimental group (vitamin C + vitamin B1) by the random number table method, with 45 cases in each group. There were 25 males and 20 females in the control group; they were 43-97 (74.0±16.64) years old. There were 33 males and 12 females in the experimental group; they were 35-94 (68.0±13.44) years old. The control group were treated with fluid resuscitation, anti-infective therapy, and primary disease treatment according to the latest guidelines for sepsis and septic shock; in addition, the experimental group were treated with high-dose vitamin C and vitamin B1. The left ventricular ejection fractions (LVEF), cardiac outputs (CO), tricuspid systolic displacements (TAPSE), and other ultrasonic results, CD3+ T lymphocyte counts, CD4+ T lymphocyte counts, CD8+ T lymphocyte counts, CD4+/CD8+ ratios, and tumor necrosis factor α (TNF-α) levels at admission to ICU (T0) and 72 hours after the treatment (T1) and the prognostic outcomes during ICU stay were compared between the two groups. χ², rank sum, and t tests were applied. Results　The TNF-α level at T1 in the experimental group were lower than that in the control group [12.96 (10.72, 19.6) vs. 17.95 (11.015, 34.75)], with a statistical difference (Z=-1.96, P<0.05). The CD3+, CD4+, and CD8+ in the experimental group were higher than those in the control group, with statistical differences (Z=-3.58, -3.15, and -3.43; all P<0.05). The CD8+ at T1 was lower than that at T0 in the control group (Z=-2.26, P<0.05). The CD3+, CD4+, and CD8+ at T1 were higher than those at T0 in the experimental group, with statistical differences (Z=-3.77, -3.89, and -2.91; all P<0.05). The improved rate in the experimental group was higher than that in the control group [71.11% (32/45) vs. 51.11% (23/45)], with a statistical difference (χ²=8.407, P<0.05). Conclusion　High-dose vitamin C combined with vitamin B1 for patients with septic shock can improve their numbers of T lymphocyte subsets, immune function, and prognosis, and reduce the production of TNF–α to some extent.

Key words:

Septic shock, T-lymphocyte subsets, High-dose vitamin C, Vitamin B1

王玉亮刘建华唐绮云.

大剂量维生素C联合维生素B1辅助治疗脓毒症休克患者的效果 [J]. 国际医药卫生导报, 2023, 29(8): 1122-1126.

Wang Yuliang, Liu Jianhua, Tang Qiyun.

High-dose vitamin C combined with vitamin B1 for patients with septic shock [J]. International Medicine and Health Guidance News, 2023, 29(8): 1122-1126.

参考文献

[1] Reinhart K,Daniels R,Kissoon N,et al.Recognizing sepsis as a global health priority - a WHO resolution[J].N Engl J Med,2017,377(5):414-417.DOI:10.1056/NEJMp1707170.
[2] Singer M,Deutschman CS,Seymour CW,et al.The third international consensus definitions for sepsis and septic shock (sepsis-3)[J].JAMA,2016,315(8):801-810.DOI:10.1001/jama.2016.0287.
[3] 郭润静,郝东.脓毒症相关生物标志物及作用机制研究进展[J].国际医药卫生导报,2022,28(10):1468-1471.DOI:10.3760/cma.j.issn.1007-1245.2022.10.033.
[4] Fath MK,Naderi M,Hamzavi H,et al.Molecular mechanisms and therapeutic effects of different vitamins and minerals in COVID-19 patients[J].J Trace Elem Med Biol,2022,73:127044.DOI:10.1016/j.jtemb.2022.127044.
[5] 熊丽荣,忻刚,姜冀.大剂量维生素C对脓毒性休克患者升压药需求的影响[J].现代实用医学,2020,32(11):1375-1377.DOI:10.3969/j.issn.1671-0800.2020.11.035.
[6] 中国医师协会急诊医师分会,中国研究型医院学会休克与脓毒症专业委员会.中国脓毒症/脓毒性休克急诊治疗指南(2018)[J].临床急诊杂志,2018,19(9):567-588.DOI:10.13201/j.issn.1009-5918.2018.09.001.
[7] Nandhabalan P,Ioannou N,Meadows C,et al.Refractory septic shock: our pragmatic approach[J].Crit Care,2018,22(1):215.DOI:10.1186/s13054-018-2144-4.
[8] Spoelstra-de Man AME,Elbers PWG,Oudemans-Van Straaten HM.Vitamin C: should we supplement?[J].Curr Opin Crit Care,2018,24(4):248-255.DOI:10.1097/MCC.0000000000000510.
[9] Zafer MM,El-Mahallawy HA,Ashour HM.Severe COVID-19 and sepsis: immune pathogenesis and laboratory markers[J].Microorganisms,2021,9(1):159.DOI:10.3390/microorganisms9010159.
[10] 王建,张炎,程璐,等.氢化可的松联合维生素C、维生素B1治疗脓毒症疗效的Meta分析[J].实用心脑肺血管病杂志,2022,30(2):95-102.DOI:10.12114/j.issn.1008-5971. 2022.00.045.
[11] Files DC,Liu KD,Matthay M.Need for additional trials of vitamin C for sepsis[J].JAMA,2020,324(6):607-608.DOI:10.1001/jama.2020.8633.
[12] 蒋小芝,齐静文,韩冰莎,等.早期补充维生素C联合氢化可的松治疗严重脓毒症的疗效分析[J].天津药学,2022,34(3):32-35.DOI:10.3969/j.issn.1006-5687.2022.03.007.
[13] Fowler AA,Truwit JD,Hite RD,et al.Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial[J].JAMA,2019,322(13):1261-1270.DOI:10.1001/jama.2019.11825.
[14] 甘斌,罗毅沣.氢化可的松联合维生素C及维生素B1在脓毒症早期患者中的临床应用价值分析[J].医药前沿,2022,12(1):13-15.
[15] 康绍涛,布祖克拉·阿布都艾尼,李英杰,等.T细胞免疫球蛋白黏蛋白分子1在脓毒症发病机制中的作用研究进展[J].中华危重病急救医学,2021,33(3):364-367.DOI:10.3760/cma.j.cn121430-20200923-00645.
[16] Marik PE.Hydrocortisone, ascorbic acid and thiamine (HAT therapy) for the treatment of sepsis.Focus on ascorbic acid[J].Nutrients,2018,10(11):1762.DOI:10.3390/nu10111762.
[17] 贺丽玲,闫新明.维生素C辅助治疗脓毒症研究进展[J].医药导报,2022,41(7):1004-1007.DOI:10.3870/j.issn. 1004-0781.2022.07.013.
[18] 向仕钊,李金,杨梁.脓毒症心肌病研究进展[J].中华心力衰竭和心肌病杂志(中英文),2019,3(1):59-61.DOI:10.3760/cma.j.issn.2096-3076.2019.01.016.
[19] 王晶,谭睿,於江泉,等.超声心动图在脓毒症心肌病中的应用进展[J/CD].中华临床医师杂志(电子版),2021,15(6):464-469.DOI:10.3877/cma.j.issn.1674-0785.2021.06.011.
[20] 于涛,冯瑛,张丽丽,等.脓毒症心肌病发病机制的研究进展[J].医学综述,2021,27(17):3363-3370.DOI:10.3969/j.issn.1006-2084.2021.17.007.
[21] 钟俊,赵佩莹,杨洵,等.维生素C用于脓毒症患者的临床疗效[J].贵州医科大学学报,2022,47(3):308-312.DOI:10.19367/j.cnki.2096-8388.2022.03.011.
[22] 占钻,黄亮,曹春水,等.大剂量维生素C对脓毒症患者心肌损伤的作用及机制[J].山东医药,2018,58(1):9-11.DOI:10.3969/j.issn.1002-266X.2018.01.003.

大剂量维生素C联合维生素B1辅助治疗脓毒症休克患者的效果

High-dose vitamin C combined with vitamin B1 for patients with septic shock

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics